Related Experiment Video

Updated: Jun 20, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma

Honghui Zhu1, Qi Lin1, Zhixian Yu1

  • 1Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Frontiers in Pharmacology
|June 19, 2026
PubMed
Abstract

Insights

This study found that ADRB1, a target of antihypertensive drugs, is associated with an increased risk of clear cell renal cell carcinoma (CCRCC). These findings may inform future CCRCC treatment strategies.

Area of Science:

  • Genetics
  • Oncology
  • Pharmacology

Background:

  • Antihypertensive drug targets have been linked to various cancers.
  • The specific relationship between these targets and clear cell renal cell carcinoma (CCRCC) risk is not well understood.

Purpose of the Study:

  • To investigate the association between antihypertensive drug targets and CCRCC risk.
  • To explore the potential role of ADRB1 in CCRCC development and prognosis.

Main Methods:

  • Summary-data-based Mendelian randomization (SMR) and colocalization analyses were performed using large genome-wide association study (GWAS) databases.
  • Meta-analysis integrated results from discovery and validation cohorts (totaling over 1 million individuals).
  • Western blotting and prognostic analyses assessed ADRB1 expression and its impact on tumor survival.

Main Results:

  • ADRB1 was significantly associated with increased CCRCC risk in both discovery and validation cohorts.
  • ADRB2 also showed an association with CCRCC risk in the discovery cohort.
  • Colocalization analyses supported shared genetic variation between ADRB1/ADRB2 and CCRCC. ADRB1 was highly expressed in CCRCC tumors and linked to poorer survival.

Conclusions:

  • ADRB1 is a potential risk factor for CCRCC.
  • The findings offer new insights into potential therapeutic targets for CCRCC.
Keywords:
antihypertensive drug targetsclear cell renal cell carcinoma riskcolocalization analysisgenetic variantsmendelian randomization

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...